JAK bar casts cloud on Glenmark’s PD-4 thrust amid revamilast setback
This article was originally published in Scrip
Executive Summary
Glenmark Pharmaceuticals’ oral phosphodiesterase-4 (PDE-4) inhibitor, revamilast (GRC 4039), has failed to meet its efficacy endpoint for rheumatoid arthritis (RA), raising doubts about its future even as the Indian firm awaits study results for revamilast in asthma later this year.